We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Galapagos NV has announced that it has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together these milestones trigger payments totaling €5.2 million to Galapagos.

This pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. The candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. The molecule is now ready for scale up chemistry and comprehensive safety evaluation, with the goal of entering Phase I clinical research in 2010.

"Six months after announcing our first pre-clinical candidate in this alliance, we are pleased to announce the delivery of a second candidate drug," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

"This achievement illustrates that Galapagos is successfully progressing multiple programs across each alliance, thereby increasing the likelihood of producing novel, disease-modifying therapeutics."